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Abstract
Recent evidence suggests that many malignancies, including breast cancer, are driven by a cellular subcomponent that
displays stem cell-like properties. The protein phosphatase and tensin homolog (PTEN) is inactivated in a wide range of
human cancers, an alteration that is associated with a poor prognosis. Because PTEN has been reported to play a role in the
maintenance of embryonic and tissue-specific stem cells, we investigated the role of the PTEN/Akt pathway in the
regulation of normal and malignant mammary stem/progenitor cell populations. We demonstrate that activation of this
pathway, via PTEN knockdown, enriches for normal and malignant human mammary stem/progenitor cells in vitro and in
vivo. Knockdown of PTEN in normal human mammary epithelial cells enriches for the stem/progenitor cell compartment,
generating atypical hyperplastic lesions in humanized NOD/SCID mice. Akt-driven stem/progenitor cell enrichment is
mediated by activation of the Wnt/b-catenin pathway through the phosphorylation of GSK3-b. In contrast to chemotherapy,
the Akt inhibitor perifosine is able to target the tumorigenic cell population in breast tumor xenografts. These studies
demonstrate an important role for the PTEN/PI3-K/Akt/b-catenin pathway in the regulation of normal and malignant stem/
progenitor cell populations and suggest that agents that inhibit this pathway are able to effectively target tumorigenic
breast cancer cells.
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Introduction
There is increasing evidence that a variety of cancers, including
those of the breast, may be driven by a component of tumor-
initiating cells that retain stem cell-like properties. These
properties include self-renewal, which drives carcinogenesis, as
well as differentiation, which contributes to tumor cellular
heterogeneity [1]. A number of signaling pathways have been
found to play a role in mammary stem cell self-renewal, including
Wnt, Notch, and Hedgehog [2–4]. In addition, the PTEN
(phosphatase and tensin homolog deleted on chromosome 10)
tumor suppressor gene, one of the most frequently mutated genes
in human malignancies, has also been suggested to play a role in
stem cell self-renewal [5]. PTEN acts as a lipid phosphatase to
dephosphorylate phosphatidylinositol (3-5)-trisphosphate (PIP3),
antagonizing the PI3-K/Akt pathway. Deletion of PTEN results in
increased activation of the PI3-K/Akt pathway, which correlates
with poor prognosis in breast cancer patients [6]. Furthermore,
deletion or reduced expression of PTEN in a wide variety of
human tumors is associated with resistance to conventional
therapeutic agents and relapse following initial treatment [7,8].
In prostate tumors, loss of PTEN expression predicts progression to
invasive and metastatic disease [9]. Deletion of PTEN in murine
models of prostate cancer results in expansion of the prostate
stem/progenitor cell population and initiation of prostate tumors
resembling those in humans [10]. In the hematopoietic system,
PTEN deletion induces excessive proliferation of hematopoietic
stem cells with subsequent depletion of this cell population in the
bone marrow [11,12]. This PTEN deficiency also results in the
induction of myeloproliferative disorders that progress to leukemia
[11,12].
Recent studies have suggested that cancer stem cells, by virtue
of their resistance to chemotherapy and radiation therapy, may
contribute to tumor resistance and relapse [13,14]. The PTEN/
PI3-K/Akt pathway has been described as a major pathway
conferring resistance to conventional therapies in multiple tumor
types [15–17]. Using a large-scale RNA interference genetic
screen, Berns et al. identified PTEN as the modulator of drug
resistance in breast cancer [17]. Patients with HER2 amplified
breast tumors that also contain PTEN deletions are resistant to
Trastuzumab treatment [8]. Because cancer stem cells have been
found to be resistant to radiation and chemotherapy, we
postulated that the PTEN/Akt pathway may play a role in the
regulation of mammary stem/progenitor cells. Thus, we examined
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the PI3-K/Akt pathway and characterized its downstream
signaling components for their role in regulating mammary
stem/progenitor cells. In the present study, we demonstrate that
the PI3-K/Akt pathway plays an important role in regulating the
Aldefluor-positive cell population, which is enriched in mammary
stem/progenitor cells, by mediating Wnt/b-catenin signaling
through phosphorylation of GSK3-b. Furthermore, we demon-
strate that the Akt inhibitor perifosine is able to target normal and
malignant Aldefluor-positive mammary epithelial cells in vitro and
in mouse xenograft models.
Results
The PTEN/PI3-K/Akt/b-Catenin Pathway Is Activated in
Mammospheres as Compared with Monolayer Cultures
We have previously demonstrated that primitive mammary stem/
progenitor cells are enriched in vitro in floating spherical colonies
termed mammospheres. Mammospheres are composed of a small
number of cells with stem cell-like properties including the ability to
form secondary mammospheres as well as the ability to undergo
multilineage differentiation [18]. In addition,we recently reported the
enrichment of mammary stem/progenitor cells within the aldehyde
dehydrogenase (ALDH)-expressing cell population as assessed by the
Aldefluor assay [19]. When these primitive mammary cells are
cultured in the presenceof serumonanadhesive substratum, they lose
these primitive properties and undergo differentiation. Recent studies
suggest that signal transduction pathways including the PTEN/PI3-
K/Akt play a role in embryonic and tissue-specific stem cell self-
renewal [10,20,21].
To determine whether this pathway was activated in primitive
mammary cells, we compared the levels of PTEN and Akt
phosphorylation and its downstream targets in normal mammary
stem and progenitor cells in mammospheres compared with those
in cells induced to undergo differentiation in monolayer cultures.
Activation of the PTEN/PI3-K/Akt pathway was assessed by
Western blotting using phospho-specific antibodies. As compared
to adherent cultures, normal mammary epithelial cells (NMECs) in
mammosphere cultures expressed increased Ser380 phosphoryla-
tion of PTEN (Figure 1A), which results in its conformational
changes masking the PDZ binding domain [22]. PTEN, through
its lipid phosphatase activity, antagonizes PI3-K/Akt signaling.
We detected increased Akt Ser473 phosphorylation in mammo-
spheres as compared with monolayer cultures, suggesting that
inactivation of PTEN results in increased Akt phosphorylation in
more primitive cells (Figure 1A). Akt has a number of known
downstream targets including GSK3-b, which regulates the Wnt/
b-catenin pathway. As compared to differentiated cells, cells in
mammospheres displayed increased levels of GSK3-b phosphor-
ylation and b-catenin activation (Figure 1A). b-catenin has been
demonstrated to play an important role in the development of
mammary stem cells in mouse models [23], suggesting that this
pathway may also be active in human mammary stem/progenitor
cells in mammospheres.
We have previously reported an enrichment of mammary stem/
progenitor cellswithin the cell population expressing ofALDH,which
can be detected by the enzymatic Aldefluor assay [19,24]. Consistent
with this, we found significantly higher ALDH expression in
mammospheres as compared to attached mammary epithelial cell
cultures (Figure 1A). We also analyzed activation of the Wnt/b-
catenin pathway in ALDH-expressing cells. Aldefluor-positive cells
showed significantly higher b-catenin activation as well as increased
GSK3-b phosphorylation as compared with Aldefluor-negative cells
(Figure S1), suggesting that mammary stem/progenitor cells display
activation of the Wnt/b-catenin pathway.
Activation of the PTEN/PI3-K/Akt Pathway Results in
Enrichment of the Mammary Stem/Progenitor Cell
Population In Vitro
To examine the functional role of the PI3-K/Akt/GSK3-b/b-
catenin pathway, we used both gain-of-function and loss-of-
function strategies. To activate this pathway, PTEN levels were
decreased by using a PTEN shRNA DsRed-labeled lentivirus.
Inclusion of the DsRed label allowed us to eliminate noninfected
cells by flow cytometry. As shown in Figure 1B, we achieved
greater than an 80% reduction in PTEN protein expression in
mammospheres as assessed by Western blotting. Knockdown of
PTEN in these cells resulted in increased levels of Akt
phosphorylation, GSK3-b phosphorylation, and b-catenin activa-
tion (Figure 1B). In addition, activation of this pathway further
increased expression of ALDH1 (Figure 1B).
To examine the functional role of the PTEN/PI3-K/Akt
pathway in human mammary stem/progenitor cell fate, we
measured the effect of PTEN knockdown on mammosphere
formation. Knockdown of PTEN resulted in an increase in the
number of primary and secondary mammospheres as compared to
control, p,0.01 (Figure 1C and 1D). Furthermore, this increase
was maintained upon serial passage to tertiary mammospheres
(Figure 1D). To provide additional evidence that this pathway
enriches for mammary stem/progenitor cells, we determined the
effect of PTEN knockdown on the percentage of cells expressing
ALDH as assessed by the Aldefluor assay. Primary NMECs from
reduction mammoplasties contain between 4% and 9% Aldefluor-
positive cells, which increases to 14%–19% in primary mammo-
spheres, consistent with the enrichment of stem/progenitor cells
when grown in suspension cultures (Figure S2A). PTEN
knockdown increased the proportion of Aldefluor-positive cells
(p,0.01) in mammospheres more than 2-fold to 37%–41%
(Figure 1E). Thus, knockdown of PTEN resulted in enrichment
of mammary stem/progenitor cells in vitro as determined by
both mammosphere and Aldefluor assays. We previously observed
that while mammary stem/progenitor cells are enriched in
Author Summary
Healthy adult tissues are maintained through the regulat-
ed proliferation of a subset of cells known as tissue stem
and progenitor cells. Many cancers, including breast
cancer, also are thought to arise from and be maintained
by a small population of cells that display stem cell-like
properties. These so-called ‘‘cancer stem cells’’ may also
contribute to tumor spread (metastasis), resistance to
treatment, and disease relapse. Effective, long-lasting
cancer treatments likely will need to target and eliminate
these cancer stem cells specifically. Regulatory pathways
responsible for maintaining cancer stem cells therefore
may be promising targets for treatment. Breast cancers in
humans frequently display abnormalities in the PTEN/PI3K/
Akt pathway. We demonstrate using cell culture and a
mouse model of breast cancer that stem or progenitor
cells in both normal breast tissue and breast tumors are
dependent for their continued growth on this pathway
and on the Wnt/b-catenin pathway. We further show that
the drug perifosine, which inhibits the kinase Akt, is able
specifically to reduce the population of breast cancer stem
or progenitor cells growing in mice. Our findings support
the idea that drugs that selectively target breast cancer
stem cells through the PTEN/PI3K/Akt pathway may
reduce tumor growth and metastasis and result in
improved patient outcomes.
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mammosphere cultures, they are depleted in attachment cultures
(Figure S2B). Cells with PTEN knockdown maintained a higher
percentage of Aldelfuor-positive cells in attachment culture (Figure
S2B) as well as in suspension culture (Figure S2A). Furthermore,
PTEN knockdown increased phospho-Akt expression in cells grown
either in attachment or suspension cultures (Figure S2C). These
results suggest that PTEN knockdown is able to enrich for the stem/
progenitor cell population independent of culture conditions.
PTEN Knockdown in NMECs Induces Morphological
Changes with Features of Atypical Hyperplasia in
Humanized NOD/SCID Mice
We previously used a mouse model described by Proia and
Kuperwasser [25] in which NMECs form outgrowths in NOD/
SCID mice whose mammary fat pads have been humanized by
the introduction of both irradiated and non-irradiated human
mammary fibroblasts. We used this system to examine the effects
of PTEN knockdown on mammary development. Serial dilutions
of flow cytometry-sorted cells were introduced into the humanized
fat pads of NOD/SCID mice. As indicated in Table S1, at all
dilutions, NMECs with PTEN knockdown were more efficient in
generating outgrowths than DsRed control cells. While at least
10,000 control cells were required for efficient outgrowth
formation, as few as 250 PTEN knockdown cells generated
outgrowths in 50% of the mice, indicating that PTEN knockdown
increased the frequency of multipotent mammary stem/progen-
itors. In addition, we observed significant morphological alter-
ations in structures generated by PTEN knockdown in NMECs
compared to DsRed controls (Figure 2A). PTEN knockdown cells
Figure 1. Activation of PTEN/PI3-K/Akt/GSK3-b/b-catenin signaling in mammospheres. (A) After 7–10 d of culture, mammospheres and
adherent NMECs were analyzed by Western blotting for activation of the PI3-K/Akt pathway and its downstream targets. Mammospheres as
compared to adherent NMEC cultures demonstrated increased phosphorylation of PTEN, Akt, GSK3-b, and activated b-catenin (ABC). Mammospheres
but not the adherent cells also expressed the marker ALDH1. (B) Knockdown of PTEN expression via shRNA lentivirus infection led to further increases
in phospho-Akt, phospho-GSK3-b, and activated b-catenin levels compared with DsRed lentiviral-infected control mammospheres. (C) PTEN
knockdown led to an increase in the number of mammosphere forming cells. The efficiency of lentivirus infection was demonstrated by DsRed
expression (inserts). (D) DsRed control and PTEN knockdown mammospheres were cultured for three passages, and the number of mammospheres
generated per 10,000 cells was determined. (E) Adherent NMECs were infected with control or PTEN lentiviral constructs and maintained in
attachment cultures for 7 d. The cells from these attachment cultures were assessed for their mammosphere-forming ability. As indicated, cells with
PTEN knockdown generated more mammospheres than control cells Scale bars in (C) = 100 mm. Each data point in (D) and (E) represents the
mean6SD of three independent experiments.
doi:10.1371/journal.pbio.1000121.g001
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produced much larger structures that displayed significant
morphologic alterations. Knockdown of PTEN was confirmed
by the lack of PTEN expression in PTEN knockdown outgrowths
compared to controls (Figure 2B, a and h). We used immunohis-
tochemical staining for markers of myoepithelial, basal, and
luminal epithelial cells to ascertain the effects of PTEN knockdown
on cellular differentiation. Outgrowths generated by control-
infected NMECs consisted of ductal structures that were
characterized by a single layer of myoepithelial cells, which
expressed smooth muscle actin recapitulating the architecture of
normal mammary ducts in humans. In contrast, structures
generated by PTEN shRNA-infected cells were characterized by
gross disorganization with increased numbers of smooth muscle
actin expressing myoepithelial cells distributed throughout the
gland (Figure 2B, b and i). Glands produced by control cells
contained only a small number of cells expressing the primitive
cytokeratins 5/6, whereas the frequency of these cells was greatly
increased in PTEN knockdown structures (Figure 2B, c and j).
Examination of epithelial markers also revealed significant
differences between structures derived from PTEN knockdown
and control cells. In control structures, the majority of the luminal
epithelial cells expressed the luminal marker CK18, whereas
expression of this marker occurred only in a subfraction of PTEN
knockdown cells (Figure 2B, d and k). Estrogen receptor (ER) was
expressed in luminal epithelial cells in structures generated from
DsRed control cells, but not in structures derived from PTEN
knockdown cells (Figure 2B, e and l). Furthermore, structures with
PTEN knockdown displayed significant increases in proliferating
cells as determined by Ki67 expression (Figure 2B, f and m).
Consistent with the in vitro experiments, PTEN knockdown also
increased the proportion of cells expressing ALDH1 (Figure 2B, g
and n). These experiments confirm and extend the in vitro findings
and suggest that in addition to resulting in enrichment of the stem/
progenitor cell pool, activation of the PTEN/PI3-K/Akt pathway
affects cellular growth and differentiation. This results in the
generation of cells displaying increased proliferation, with aberrant
differentiation resulting in increased expression of primitive and
basal markers and decreased expression of luminal epithelial
Figure 2. Knockdown of PTEN in NMECs generates disorganized hyperplastic lesions in humanized NOD/SCID mice. (A) Human
mammary outgrowths generated from control or PTEN knockdown NMECs in humanized NOD/SCID mice exhibited an altered morphology by
hematoxylin and eosin staining. (B) PTEN staining demonstrated reduced PTEN protein expression in outgrowths generated from PTEN knockdown
cells as compared to the controls (a and h). Smooth muscle actin (SMA) staining revealed disorganized myoepithelial structures in PTEN knockdown
outgrowths compared to an organized layer of myoepithelial cells in controls (b and i). Outgrowths with PTEN knockdown showed increased CK5/6
expression (c and j) and decreased CK18 expression (d and k), as well as a lack of ERa expression compared to control cells (e and l). PTEN knockdown
outgrowths displayed increased proliferation characterized by Ki67 staining compared to controls (f and m). Increased ALDH1 expression was
demonstrated in PTEN knockdown structures (g and n). Scale bars = 100 mm. Data are representative of experiments with five mice in each group.
doi:10.1371/journal.pbio.1000121.g002
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markers. All of these histopathologic features are characteristic of
atypical ductal hyperplasia, a premalignant lesion that may
progress to invasive breast cancer.
Inhibition of PI3-K/Akt Signaling Suppresses
Mammosphere Formation In Vitro and Generation of
Outgrowths in NOD/SCID Mouse
To further characterize the pathways regulating mammary
stem/progenitor cell self-renewal, we used inhibitors of PI3-K/Akt
signaling as well as its downstream targets, GSK3-b and
mammalian target of rapamycin (mTOR). As demonstrated in
Figure 3A, treatment of NMECs with the PI3-K inhibitor
LY294002 or the Akt inhibitor IV or perifosine reduced the
number of both primary (unpublished data) and secondary
mammospheres (p,0.001). Furthermore, primary mammospheres
treated with inhibitors of PI3-K or Akt completely failed to form
tertiary mammospheres (unpublished data). To determine whether
the mTOR pathway, which is downstream of Akt signaling, plays
a role in this process, we examined the effect of rapamycin, an
inhibitor of this pathway, on mammosphere formation. As shown
in Figure 3A and Figure S2, rapamycin had little effect on
secondary mammosphere formation, suggesting that mTOR was
not responsible for mediating the effects of Akt signaling. In
contrast to rapamycin, PI3-K and Akt inhibitors suppressed the
formation of secondary mammospheres in both control and PTEN
knockdown NMECs, supporting the importance of this pathway in
mammary stem/progenitor cell self-renewal (Figure 3A). To
determine whether PTEN knockdown affected cellular sensitivity
to Akt inhibition, we performed dose response studies with
perifosine. As shown in Figure 3B, 2 mM perifosine inhibited Akt
phosphorylation by more than 50% in PTEN knockdown cells
while having no demonstrable effect on control cells. Consistent
with the effects on mammosphere formation, the Akt inhibitor
perifosine significantly reduced the proportion of Aldefluor-
positive cells in mammospheres (Figure 3C). The effect of
perifosine on PI3-K/Akt signaling has previously been reported
[26,27]. In that study, the authors found that 10 mM perifosine did
not have any inhibitory effect on the MAPK pathway [27]. We
also failed to detect an effect of perifosine on MAPK activity in our
system (unpublished data).
To determine whether the PI3-K/Akt pathway was also critical
for mammary development in vivo, we examined the effect of
the Akt inhibitor perifosine on the development of human
mammary structures generated by control DsRed infected or
Figure 3. Effect of PI3-K/Akt inhibitors on mammosphere formation, ALDH1 expression, and mammary development in NOD/SCID
mice. (A) Treatment of mammospheres with the PI3-K inhibitor LY294002 (1 mM), Akt inhibitor IV (2 mM), or perifosine (5 mM) inhibited
mammosphere formation in control cells, whereas PTEN knockdown NMECs were sensitive to lower doses of these inhibitors: LY294002 (0.5 mM), Akt
inhibitor IV (1 mM), or perifosine (2 mM). In contrast, the mTOR inhibitor rapamycin (0.5 mM) had little effect on these cells. (B) Perifosine dose
response was tested in both control and PTEN knockdown cells. As indicated, PTEN knockdown cells with higher Akt activity are more sensitive to
perifosine than control cells with an IC50 of 5 mM. (C) The effect of perifosine on the Aldefluor-positive population of NMECs was measured by the
Aldefluor assay. Treatment of NMECs with perifosine over 5 d reduced the Aldefluor-positive population in primary mammospheres by more than
50%. (D) Perifosine treatment of mice implanted with control or PTEN knockdown NMECs completely blocked the formation of outgrowths in NOD/
SCID humanized fat pads compared to saline-treated control mice. High magnification (insets) shows persistence of the inoculated cells. Scale
bars = 100 mm. Data represent the mean6SD of three independent experiments.
doi:10.1371/journal.pbio.1000121.g003
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PTEN knockdown NMECs. NOD/SCID mice implanted with
control or PTEN knockdown NMECs were treated with
intraperitoneal injections of perifosine (30 mg/kg) 4 days a week
for five weeks or a saline control. Consistent with previous
experiments, control DsRed NMECs generated mammary ductal
structures with normal morphology, PTEN knockdown NMECs
generated ductal hyperplasias in saline-treated control mice. In
contrast, administration of perifosine completely inhibited out-
growth formation by both control and PTEN knockdown NMECs
(Figure 3D). These results further support the in vitro experiments
by demonstrating a critical role for Akt signaling in normal
mammary development.
Effects of PI3-K/Akt on Mammary Stem/Progenitor Cells
Are Mediated by GSK3-b/b-Catenin Signaling
Activated Akt has been demonstrated to be capable of
phosphorylating and inactivating GSK3-b, leading to nuclear
translocation and activation of b-catenin [28,29]. In addition, Akt
can directly phosphorylate b-catenin, an event which further
facilitates its nuclear translocation [21]. Since Wnt signaling
through b-catenin has been shown to play a role in mammary
development and stem cell self-renewal, we examined whether Akt
effects on mammary stem/progenitor cells were mediated by this
pathway. To examine the role of Wnt/b-catenin signaling, we
used the GSK3-b inhibitor 6-bromoindirubin-39-oxime (Bio),
which has been shown to be able to maintain pluripotency of
human and mouse embryonic stem cells through activation of b-
catenin signaling [30]. We first confirmed that addition of Bio to
NMECs resulted in phosphorylation of GSK3-b with subsequent
activation of b-catenin (Figure 4A). To determine the biological
relevance of this pathway, we examined the effects of Bio on
mammosphere formation. As shown in Figure 4B, the addition of
Bio increased mammosphere formation 2-fold. In addition, the
reduction of mammosphere formation induced by perifosine was
reversed by the addition of Bio (Figure 4B). Reversal of inhibition
occurred despite the persistent inhibition of Akt activity in the
presence of both compounds (Figure 4A). To confirm the
importance of b-catenin signaling in stem/progenitor cell self-
renewal, we knocked down b-catenin expression by using an
shRNA lentivirus (Figure S3). Lentiviral shRNA-mediated down-
regulation of b-catenin expression in NMECs reduced the number
of mammospheres by approximately 70% (Figure 4B). These
experiments suggest that the effects of Akt on mammary stem/
progenitor cell self-renewal are mediated through GSK3-b/b-
catenin signaling.
To provide further evidence for cross-talk between Akt signaling
and the Wnt pathway, we used a LEF-1/TCF reporter system to
monitor b-catenin transcriptional activity in PTEN knockdown or
Bio-treated NMECs. NMECs were infected with a LEF-1/TCF
reporter driving GFP (TOP-GFP) or a control reporter with
mutated LEF-1/TCF binding sites (FOP-GFP). Approximately 2–
5% of cells in mammospheres expressed GFP (Figure 4C), whereas
FOP-GFP-infected NMECs did not express GFP (Figure 4D). Bio
treatment increased the percentage of GFP-positive cells in
mammospheres more than 2-fold, confirming that GSK3-b
plays a role in nuclear translocation and activation of b-catenin
(Figure 4C and 4D). In addition, when cells were co-infected
with lentiviral PTEN shRNA and TOP-GFP, the percentage
of GFP-expressing cells increased more than 2-fold (Figure 4C).
To confirm that Akt regulates mammary stem/progenitor
cells by activating b-catenin signaling, TOP-GFP infected cells
were treated with perifosine or Bio alone or in combination.
Perifosine treatment reduced the proportion of GFP-positive
cells by more than 50%, whereas Bio treatment increased
the number of GFP-expressing cells more than 2-fold as
assessed by flow cytometry (Figure 4D). Bio reversed the
effect of perifosine when mammospheres were treated with a
combination of perifosine and Bio (Figure 4D). The role of b-
catenin signaling in mammary stem/progenitor cells was further
investigated by examining the b-catenin activity and nuclear
localization in Aldefluor-positive and -negative populations. As
shown in Figure S1, Aldefluor-positive but not Aldefluor-negative
cells displayed GSK3-b phosphorylation and nuclear b-catenin
localization.
To extend these observations to the mouse models, we
examined the expression and localization of phospho-Akt and b-
catenin in mammary outgrowths generated from control and
PTEN knockdown NMECs. As shown in Figure 4E, control
outgrowths contained cells with low levels of phospho-Akt and
membranous b-catenin staining. In contrast, outgrowths generated
from PTEN shRNA lentivirus-infected cells demonstrated in-
creased phospho-Akt expression and nuclear b-catenin localization
(Figure 4E). Together, these experiments demonstrate that Akt
effects on mammary stem/progenitor cells are mediated by
GSK3-b/b-catenin signaling.
Akt Activation Enriches the Tumorigenic Stem/Progenitor
Cell Population in Breast Cancer Cell Lines and Tumor
Xenografts
By using primary mammary carcinoma xenografts, we previ-
ously demonstrated that cancer cells with stem cell-like properties
were contained within the Aldefluor-positive population [19].
Recent studies have suggested that established breast cancer cell
lines also contain subpopulations with stem cell-like properties. In
MCF7 and SUM159 cell lines, we previously demonstrated that
only the Aldefluor-positive populations were able to form tumors
capable of serial passaging in NOD/SCID mice [31]. To
determine whether the PTEN/PI3-K/Akt pathway played a
similar role in the regulation of malignant mammary stem/
progenitor cells to that of normal mammary stem/progenitor cells,
we determined the effect of knocking down PTEN expression on
the cancer stem/progenitor cell populations in these cell lines. As
shown by Western blotting (Figure 5A), control MCF7 cells
expressed PTEN, but not phospho-Akt. Knockdown of PTEN
with an shRNA lentivirus resulted in Akt activation (Figure 5A).
SUM159 cells display a baseline level of phospho-Akt expression,
which was further enhanced by PTEN knockdown (Figure 5A). To
determine whether reduction of PTEN expression affected the
mammary cancer stem/progenitor cell components of these cell
lines, we used tumorsphere and Aldefluor assays. As shown in
Figure 5B, knockdown of PTEN increased tumorsphere formation
in both MCF7 and SUM159 breast carcinoma cells. Furthermore,
this knockdown resulted in more than a 2-fold increase in the
Aldefluor-positive population (p,0.01) in these cell lines
(Figure 5C). We confirmed that PTEN knockdown in MCF7
xenographs resulted in increased Akt phosphorylation (Figure
S4B). Subsequently we determined whether the increase in the
cancer stem/progenitor cell population resulting from PTEN
knockdown resulted in increased tumorigenicity. As shown in
Figure S4A and S4C, PTEN knockdown in MCF7 or SUM159
cells increased their tumorigenicity in NOD/SCID mice. Since
Zhou et al. previously reported that the side population (SP) in
MCF7 contained tumor-initiating cells, we examined the overlap
between the SP and Aldefluor-positive populations. As demon-
strated in Figure S4, we found a 2-fold enrichment of Aldefluor-
positive population in the MCF7 SP population as compared to
non-SP cells. This suggests that the Aldefluor and SP assays detect
PTEN/Akt Regulates Mammary Stem/Progenitor Cells
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distinct, but partially overlapping, cell populations. We previously
reported that tumorigenicity in these cell lines is mediated by the
Aldefluor-positive population, which is enriched for tumorigenic
cancer stem/progenitor cells [31]. Thus, these results suggest that
Akt activation increases tumorigenicity through effects on the
cancer stem/progenitor cell population. We next used the
TOP-GFP reporter system to determine whether Akt signals
through the Wnt/b-catenin pathway in breast carcinoma cells.
Perifosine treatment of TOP-GFP-infected SUM159 breast cancer
cells resulted in a significant decrease in GFP-positive cells
(p,0.01), whereas treatment of these cells with Bio increased the
proportion of GFP-positive cells 3-fold, p,0.01 (Figure 5D). As
was the case for normal mammary cells, Bio treatment was able to
reverse the effect of perifosine in these mammary carcinoma cells
(Figure 5D).
Perifosine Treatment Reduces the Proportion of
Aldefluor-Positive Cells in Breast Carcinoma Xenografts
To determine whether Akt also drives the tumorigenic
Aldefluor-positive cell population in vivo, we examined the effects
of the Akt inhibitor perifosine on the growth of SUM159 breast
cancer cells in NOD/SCID mouse xenografts. SUM159 cells are
more tumorigenic than MCF7 cells, which may relate to their
higher level of Akt phosphorylation. In addition, to extend this
study to primary tumor xenografts, we examined the effects of this
Figure 4. PTEN regulates b-catenin activity in mammary stem/progenitor cells. (A) Effects of the GSK3-b inhibitor (Bio) and the Akt inhibitor
(perifosine) on activation of Akt/GSK3-b/b-catenin signaling as assessed by Western blotting using phospho-specific antibodies. Perifosine inhibits
pAkt, pGSK3-b, and activated b-catenin expression. The GSK3-b inhibitor Bio restores b-catenin activation even in the presence of perifosine. (B) After
5 d treatment of primary mammospheres with either 10 mM perifosine or 0.5 mM Bio alone or in combination, cells were dissociated and passaged to
form secondary mammospheres. Bio treatment increased the number of secondary mammospheres more than 2-fold, whereas perifosine treatment
or down-regulation of b-catenin via infection with an shRNA lentivirus decreased the number of secondary mammospheres by more than 50%. Bio
reversed the inhibitory effect of perifosine. (C) To monitor b-catenin activity, TOP-GFP reporter lentivirus-infected mammospheres were treated with
Bio or co-transfected with PTEN shRNA. Control mammospheres cultured for 7 d contained one–four GFP-positive cells. The proportion of GFP-
positive cells was increased more than 2-fold by Bio treatment. Knockdown of PTEN also resulted in more than a 2-fold increase in the proportion of
GFP-positive cells. (D) TOP-GFP infected mammospheres were treated for 5 d with indicated compounds either alone or in combination and analyzed
by flow cytometry. Perifosine treatment decreased the proportion of GFP-positive cells by more than 50%, whereas Bio treatment increased them
more than 2-fold. The inhibition produced by perifosine was abrogated when the mammospheres were also treated with Bio. (E) Outgrowths
generated in NOD/SCID mice from PTEN shRNA lentivirus-infected cells displayed increased phospho-Akt expression as well as increased nuclear b-
catenin localization as compared to control outgrowths. Scale bars = 100 mm. Data represent the mean6SD of three independent experiments.
doi:10.1371/journal.pbio.1000121.g004
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inhibitor on two different breast cancer xenografts, MC1 and
UM2, in which we previously demonstrated that the tumorigenic
cells are contained within the Aldefluor-positive population [19].
We compared the effects of perifosine alone or with docetaxel, a
chemotherapeutic agent that is commonly used to treat human
breast cancers. As shown in Figure 6, both perifosine and
docetaxel significantly inhibited tumor growth in all three
xenografts compared with saline-treated controls. Furthermore,
the combination of perifosine and docetaxel reduced tumor size
compared with either treatment alone (Figure 6A–6C). After 4 wk
of treatment, animals were killed, and cells in the residual tumors
were analyzed by the Aldefluor assay. Treatment of mice with
docetaxel had no significant effect on the percentage of Aldefluor-
positive cells. In contrast, perifosine either with or without
docetaxel significantly (p=0.001) reduced the Aldefluor-positive
population by over 75% in Sum159 and MCI (Figure 6A and 6B)
and over 90% in UM2 xenografts (Figure 6C). (Flow cytometry
data are presented in Figure S6A–S6C).
To determine whether these treatments affected the Wnt/b-
catenin pathway, we examined their effects on b-catenin
expression and cellular localization. Nuclear b-catenin was
detected in the majority of cells from control and docetaxel-
treated animals. In contrast, tumors treated with perifosine or the
combination of perifosine and docetaxel showed a significant
reduction in b-catenin expression that was largely localized in the
cytoplasm or plasma membrane rather than nucleus (Figure 6D).
Although cancer stem cells are enriched within the Aldefluor-
positive cell population, a more definitive assay for breast cancer
stem cells involves their ability to self-renew as determined by
tumorigenicity in NOD/SCID mice. We therefore determined the
ability of serial dilutions of cells obtained from control or treated
tumors to form secondary tumors in NOD/SCID mice. Figure 7A
and 7B demonstrate that tumor cells derived from docetaxel-
treated or control animals showed similar tumor regrowth at all
dilutions in secondary NOD/SCID mice. In contrast, perifosine
treatment with or without chemotherapy significantly reduced
tumor growth in secondary recipients (Figure 7A and 7B). When
equal numbers of cells were injected, those from perifosine treated
animals showed a 2–3-fold reduction (For 56104 cells; p,0.01, for
16104 cells; p=0.05, and for 16103 cells; p=0.01) in tumor
growth compared to cells from chemotherapy treatment alone or
control animals (Figure 7A and 7B and Figure S6). Furthermore,
in contrast to cells obtained from docetaxel treatment or control
animals, 1,000 cells from perifosine or the combination of
perifosine- and docetaxel-treated animals failed to produce tumors
in secondary mouse xenografts (Figure 7A and 7B). The kinetics of
secondary tumor growth at different inoculation dilutions are
shown in Figure S7A and S7B. Thus, the Aldefluor assay as well as
tumor regrowth experiments indicate that perifosine is able to
target and reduce the Aldefluor-positive population, whereas one
of the most commonly used chemotherapeutic agents, docetaxel,
failed to do so.
To determine whether perifosine treatment selected for a
resistant population of tumor stem/progenitor cells, cells from
tumors remaining after perifosine or docetaxel treatment were
sorted by the Aldefluor assay and reimplanted in secondary
NOD/SCID mice. As we have previously reported [19], only
Aldefluor-positive cells were tumorigenic in NOD/SCID mice
Figure 5. Knockdown of PTEN in breast cancer cell lines results in enrichment of breast cancer stem/progenitor cells via the Akt/
GSK3-b/b-catenin pathway. (A) PTEN knockdown in MCF7 or SUM159 cells resulted in increased Akt phosphorylation as assessed by Western
blotting. (B) PTEN knockdown resulted in increased secondary tumorsphere formation in MCF7 and SUM159 cells. (C) PTEN knockdown secondary
tumorspheres contained an increased proportion of Aldefluor-positive cells as compared with the tumorspheres from parental lines. (D) Flow
cytometry analyses of TOP-GFP-infected SUM159 tumorspheres treated with indicated inhibitors. Perifosine treatment decreased the proportion of
GFP-positive cells by more than 50%, whereas Bio treatment increased the proportion of GFP-positive cells more than 2-fold and reversed the
inhibitory effect of perifosine. Data represent the mean6SD of three independent experiments.
doi:10.1371/journal.pbio.1000121.g005
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(Figure 7C). Furthermore secondary tumors generated from
perifosine- or docetaxel-treated tumors were as sensitive to
perifosine as were primary tumors (Figure 7C). Together these
studies indicate that perifosine is able to significantly reduce the
tumorigenic cell population without selecting for resistant cells.
Discussion
The cancer stem cell hypothesis holds that cancer arises in tissue
stem or progenitor cells through dysregulation of the self-renewal
process [32,33]. This process generates tumors organized in a
cellular hierarchy that are driven by ‘‘cancer stem cells,’’ which are
capable of self-renewal as well as differentiation, generating the
bulk of the tumor. Although considerable progress has been made
in identifying ‘‘cancer stem cells’’ in a variety of hematologic and
solid human malignancies, the pathways that drive transformation
of these cells are poorly understood. We and others have suggested
that carcinogenesis may involve dysregulation of the normally
tightly regulated process of stem cell self-renewal coupled to
aberrant differentiation of progeny cells [1].
The PTEN tumor suppressor gene is one of the most frequently
dysregulated genes in breast cancer. Mouse genetic studies reveal
that PTEN is essential for embryonic development [5], with
heterozygous mice developing tumors in several organs including
the breast [5,34]. Germline mutations of PTEN cause cancer
predisposition and a rare developmental disease called Cowden
syndrome, which is associated with an increased incidence of
breast cancer [35]. Humans with germline BRCA1 mutations may
also develop microdeletions in the PTEN gene [36]. There is also
accumulating evidence that PTEN may play a role in stem cell self-
renewal [37].
We have used both in vitro systems and mouse models to
demonstrate an important role for the PTEN/PI3-K/Akt/b-
catenin pathway in regulating both normal and malignant
Figure 6. Perifosine targets the Aldefluor-positive cell population in breast cancer xenografts. (A–C). 50,000 cells from SUM159 cell line
or two breast cancer xenografts, MCI, or UM2 were injected into NOD/SCID mice and the tumor size was monitored. When the tumors were
approximately 4 mm, perifosine (30 mg/kg) or docetaxel (10 mg/kg), or a combination of the two agents were administered intraperitoneally once
per week. Tumor size before and during the course of each indicated treatment is shown. (D) ALDH activity was assessed by the Aldefluor assay.
Control or docetaxel-treated SUM159, MCI, or UM2 tumor xenografts contained a fraction of cells ranging from 4–8%, which displayed Aldefluor
activity. In contrast, perifosine treatment alone or in combination with docetaxel produced a 75–90% decrease in the proportion of cancer stem/
progenitor cells as assessed by the Aldefluor assay. (E) Effect of treatment on b-catenin expression. Control and docetaxel-treated tumors displayed
abundant nuclear b-catenin expression. This was significantly reduced by perifosine treatment. Scale bars = 100 mm. Data represent the mean6SD of
experiments with five mice in each group.
doi:10.1371/journal.pbio.1000121.g006
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mammary stem/progenitor cells. Compared with differentiated
normal mammary epithelial cells in monolayer cultures, mammo-
spheres displayed significantly higher levels of Akt phosphoryla-
tion. This was accompanied by increased GSK3-b phosphoryla-
tion and b-catenin activation, suggesting that the b-catenin
signaling pathway may have a role in maintaining mammary
stem/progenitor cell population. The Wnt/b-catenin pathway has
previously been shown to play a role in mammary stem cell
function in transgenic mouse models [38]. To examine the role of
these signaling pathways in mammary stem cell function, we used
both gain-of-function and loss-of-function approaches. Knock-
down of PTEN using a PTEN shRNA lentiviruses resulted in an
enrichment of mammary stem/progenitor cells in vitro as
evidenced by mammosphere formation and by the expression of
ALDH as assessed by the Aldefluor assay [19]. Increases in
percentage of Aldelfuor-positive cells and mammosphere forma-
tion were seen in PTEN knockdown cells even when they were
initially cultured in attached conditions, indicating that PTEN
knockdown maintains a higher proportion of mammary stem/
progenitors. We have previously demonstrated an enrichment of
stem/progenitor cells within the Aldefluor-positive cell population
as well as in mammospheres [19,39]. We next examined the effects
of Akt activation via PTEN knockdown on the formation of
mammary outgrowths in NOD/SCID mice whose mammary
glands were humanized by the introduction of human mammary
fibroblasts [19,25]. Control structures generated from DsRed-
infected NMECs were composed of CK18+ epithelial cells, a
portion of which also expressed ERa, surrounded by a single layer
of smooth muscle actin expressing myoepithelial cells. These
structures closely resembled those found in normal human
mammary ducts. In contrast, PTEN shRNA lentivirus-infected
cells generated hyperplastic structures exhibiting gross tissue
disorganization. This was characterized by an increase in cells
expressing primitive cytokeratins 5 and 6 and a decrease in cells
expressing the luminal marker CK18, indicating an expansion of
primitive cells. This was further evidenced by a lack of ERa
expression. Furthermore, these disorganized structures contained
an increased proportion of proliferating cells, as evidenced by
Ki67 expression and an expansion of ALDH1-expressing cells. All
of these histologic characteristics resembled those of atypical
ductal hyperplasia, one of the most common premalignant lesions
in humans that is believed to be a precursor of DCIS (ductal
carcinoma in situ) and invasive ductal carcinoma [40]. Interest-
ingly, inactivating mutations of PTEN have been reported to be
present in these preneoplastic lesions in humans [41]. Our studies
provide a potential molecular explanation for these findings by
suggesting that PTEN knockdown and subsequent Akt activation
may regulate mammary stem cell self-renewal with an accompa-
nying alteration in cellular differentiation, events which may be
important during the initiating stages of carcinogenesis.
Utilizing the SP from MCF7 cells, Zhou et al., recently
suggested that the PTEN/mTOR/STAT3 pathway is required
for the maintenance of breast cancer stem cells [42]. We detected
a 2-fold enrichment of Aldefluor-positive cells in the SP
population, suggesting that these assays detect distinct, although
partially overlapping, cell populations. We found no evidence for
mTOR regulation of normal or malignant mammary stem/
progenitor cells. There might be several explanations for this
discrepancy. A number of reports have indicated that inhibition of
mTOR results in the activation of Akt through a positive-feedback
Figure 7. Perifosine treatment reduces the tumorigenic cell population as assessed by reimplantation in secondary NOD/SCID
mice. (A and B). Serial dilutions of cells obtained from primary Sum159 (A) or MCI (B) tumors treated with saline control, perifosine, docetaxel, or both
were implanted into secondary NOD/SCID mice. Control and docetaxel-treated primary tumors formed secondary tumors at all dilutions. In contrast,
primary tumors treated with perifosine alone or in combination with docetaxel demonstrated growth delay with secondary tumors that were three
times smaller in size than the control or docetaxel-treated tumors. Furthermore, 1,000 cells from perifosine or perifosine- plus docetaxel-treated
primary tumors failed to form any secondary tumors, whereas tumors grew in mice inoculated with an equivalent number of cells from control or
docetaxel-treated tumors. (C) Primary treated tumors were sorted by the Aldefluor assay and 56103 cells from each of the Aldelfuor-positive and
Aldelfuor-negative populations were reimplanted in secondary NOD/SCID mice. Only Aldefluor-positive cells generated secondary tumors that
remained sensitive to perifosine treatment. Data represent the mean6SD of experiments with five mice in each group.
doi:10.1371/journal.pbio.1000121.g007
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loop [43–46]. Furthermore, recent studies have shown that
mammary stem cells are not contained within the SP population
[47]. In contrast to the report by Zhou et al., we used both
pharmacologic and genetic approaches to elucidate the down-
stream signaling pathways of Akt in both normal and malignant
mammary stem/progenitor cells. Treatment of NMECs with the
PI3-K inhibitor Ly294002, or the Akt inhibitors IV and perifosine,
reduced mammosphere formation and the Aldefluor-positive cell
population. The effect of perifosine on the PI3-K/Akt pathway has
previously been described [26,48]. It has also been reported that
Akt may regulate Wnt signaling through Akt phosphorylation and
inactivation of GSK3-b, which in turn mediates b-catenin
degradation [28] or, directly by phosphorylating b-catenin on
serine 552, promoting the nuclear translocation of b-catenin [21].
Thus, by these two mechanisms, Akt activation promotes the
activation and accumulation of nuclear b-catenin [49]. We
demonstrated in mammospheres that Akt phosphorylation was
associated with increased phosphorylation of GSK3-b and
activation of b-catenin. GSK3-b targets b-catenin for ubiquitin-
mediated degradation through phosphorylation of its N-terminal
serine and threonine residues [50]. To demonstrate the impor-
tance of b-catenin in mammosphere formation, we used a b-
catenin shRNA lentivirus to knock down b-catenin expression.
This resulted in significantly reduced mammosphere formation.
Furthermore, we demonstrated that the GSK3-b inhibitor Bio
rescued the effects of Akt inhibition on mammosphere formation.
To examine more directly the activation of the Wnt pathway, we
used a TOP-GFP reporter system that is activated by b-catenin
signaling. The Akt inhibitor perifosine significantly reduced the
proportion of TOP-GFP expressing cells, an effect that was
reversed by Bio. The relevance of these findings to mammary
development in vivo was determined by examining the expression
and cellular localization of phospho-Akt and b-catenin in
mammary outgrowths generated from control and PTEN
knockdown NMECs. While cells from control outgrowths showed
minimal phospho-Akt expression and membranous b-catenin
localization, outgrowths from PTEN shRNA lentivirus-infected
cells demonstrated increased phospho-Akt expression and nuclear
b-catenin localization. The importance of this pathway was
demonstrated by the ability of the Akt inhibitor perifosine to
completely block mammary development in the mouse model.
Together these in vitro and mouse experiments suggest that the
effects of Akt on mammary stem/progenitor cells are mediated by
GSK3-b phosphorylation and b-catenin activation.
To determine whether the PTEN/Akt/b-catenin signaling
pathway also plays a role in the regulation of malignant mammary
stem/progenitor cells, we used both breast cancer cell lines and a
primary tumor xenograft. Although Hollestelle et al. reported an
activating PIK3CAmutation in MCF7 cells, they did not determine
whether this mutation resulted in activation of the PI3K/Akt
pathway [51]. In contrast, Neve et al. screened 38 breast cancer
cell lines including MCF7 for various pathways and found that
MCF7 cells displayed significantly low levels of the PI3/Akt
activation when compared with other cell lines [52]. This was
confirmed in a recent report demonstrating that despite harboring
a PIK3CA helical mutation, MCF7 cells displayed a low level of
AKT phosphorylation [53]. In addition, these authors found no
correlation between similar activating mutations of PIK3CA in
primary tumors and patient survival or the chemoresistance [53].
Most importantly, they found no evidence that these mutations in
PIK3CA resulted in activation of Akt pathway as compared with
the wild-type PIK3CA, but there was a strong correlation between
PTEN inactivating mutation and activation of Akt signaling [53].
In agreement with latter reports, we found that PTEN knockdown
in MCF7 or SUM159 resulted in activation of PI3-K/Akt
pathway. We demonstrated that activation of this pathway
through knockdown of PTEN significantly increased tumorsphere
formation and the ALDH-expressing cell population, indicating an
enrichment of cancer stem/progenitor cells. Moreover, enrich-
ment of the cancer stem/progenitor cell population directly
correlated with increased tumorigenicity. Since this population
mediates tumorigenesis [31], it suggests that Akt activation
enhances tumorigenesis through effects on the cancer stem/
progenitor cell population. Furthermore, as was the case for
NMECs, we demonstrated that Akt effects on mammary
carcinoma stem/progenitor cells are mediated by Wnt/b-catenin
signaling. By using the TOP-GFP reporter system, we found that
inhibition of Akt signaling significantly reduced the number of
GFP-positive cells, an effect that was rescued with the GSK3-b
inhibitor Bio. These findings are in agreement with the findings of
Li et al., who reported that Wnt-induced mouse mammary tumors
show expansion of stem/progenitor population as characterized by
increased stem cell markers [54]. Furthermore the Wnt/b-catenin
pathway has been shown to play a role in mediating the radiation
resistance of mouse mammary progenitor cells [55].
In addition to its effects on the stem/progenitor cell population,
Akt has been demonstrated to play a role in chemoresistance [15–
17]. Recent evidence utilizing in vitro systems [56], animal models
[13], and clinical trials have suggested that breast cancer stem cells
are relatively resistant to both radiation and chemotherapy [57].
Improved clinical outcomes may require the development of
strategies that are able to target this cancer stem cell population.
The demonstration that Akt signaling plays a prominent role in stem
cell self-renewal makes it an attractive target for such strategies. We
used the Akt inhibitor perifosine, an orally bioactive alkylpho-
spholipid, to determine its effects on Aldefluor-positive cell
population. We demonstrate both in in vitro and in mouse
xenograft models that perifosine is able to target the Aldefluor-
positive tumorigenic cell population as determined by the Aldefluor
assay and by reduced tumorigenicity upon serial transplantation.
Furthermore, tumorigenic Aldefluor-positive cells remaining after
perifosine treatment generated secondary tumors that were still
sensitive to perifosine. In contrast, the chemotherapeutic agent
docetaxel, although capable of causing tumor regression, failed to
target the Aldefluor-positive cell population. If cancer stem cells
indeed contribute to tumor resistance and relapse, then the addition
of agents that are capable of targeting these cells may increase the
clinical efficacy of current therapies. Our studies identify inhibitors
of the PI3-K/Akt/Wnt signaling pathway as potential agents for
therapeutic targeting of cancer stem cells.
Materials and Methods
Cell Lines and Reagents
The MCF7 cell line was maintained in RPMI supplemented
with 5% fetal bovine serum (FBS), 5 mg/ml insulin, and antibiotic-
antimycotic. The SUM159 cell line was maintained in Ham’s F12
medium supplemented (with 5% FBS, 5 mg/ml insulin, 1 mg/ml
hydrocortisone, and antibiotic/antimycotic 10,000 units/ml
penicillin G sodium, 10,000 mg/ml streptomycin sulfate, and
25 mg/ml amphotericin B). LY294002, Akt inhibitor IV, and Bio
were purchased from Millipore; perifosine was obtained from
Keryx Biopharmaceuticals, and docetaxel (Taxotere) was from
Sanofi Aventis.
Antibodies to phospho-Akt, Akt, b-catenin, GSK3-b, phospho-
GSK3-b Ser9, PTEN, and phospho-PTEN Ser380 were purchased
from Cell Signaling Technology. The a-tubulin antibody was from
Santa Cruz Biotechnology, the ALDH1 antibody was from BD
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Transduction Laboratory, and the active-b-catenin (anti-ABC),
clone 8E7 mouse monoclonal antibody was from Millipore
Corporation.
The primary antibodies for human smooth muscle actin, Ki67,
CK5/6, and CK18 were purchased from Zymed laboratories
(Invitrogen).
Dissociation of Normal Mammary Tissues
Mammary tissue from reduction mammoplasties was dissociat-
ed as previously described [19]. The single-cell suspension was
used for various experiments including sphere formation, flow
cytometry analyses, and lentiviral infections. At least three
different patient samples (reduction mammoplasties) were used
for each experiment involving NMECs.
Mammosphere/Tumorsphere Assay
Single NMECs were plated on 1% agarose coated plates at a
density of 16105 cells/ml and grown for 7–10 d. Subsequent
cultures after dissociation of primary spheres were plated on
ultra-low attachment plates at a density of 56103–16
104 cells/ml. Mammosphere cultures were grown in a serum-free
mammary epithelium basal medium as previously described [18].
Tumorspheres were cultured under identical conditions to
mammospheres.
Lentiviral Constructs and Infection of NMECs and Breast
Cancer Cell Lines
All lentiviral constructs were prepared by the University of
Michigan Vector or shRNA core facilities. The primers targeting
the human PTEN short hairpin sequences were purchased from
Integrated DNA Technologies. The forward primer TCCCA-
GGTGAAGGTATGTTCCTCCAATCTAAAGGATTGGAGG-
AATATATCTTCACCTGGGATTTTTTC and the reverse
primer TCGAGAAAAAATCCCAGGTGAAGATATATTCC-
TCCAATCCTTTAGATTGGAGGAACATACCTTCACCTG-
GAC were digested with the Xho1 enzyme, annealed, and cloned
into the pLentilox 3.7 vector. After confirmation of DNA
sequences, the vectors were infected into 293 host cells to produce
viruses at the University of Michigan Vector Core facility.
Resulting lentiviral PTEN shRNA has been used to transfect
NMECs and breast cancer cell lines. Two different CTNNB1
shRNA lentiviral vectors were purchased from University of
Michigan shRNA core facility. TOP-GFP and FOP-GFP lentiviral
reporter vectors were kindly provided by Irving L. Weissman
(Stanford University School of Medicine, Stanford, California).
Aldefluor Assay and Flow Cytometry
To measure and isolate cells with high ALDH activity, the
Aldefluor assay was carried out according to manufacturer’s
(Stemcell Technologies) guidelines. Briefly, dissociated single cells
from cell lines or from primary mammospheres were suspended in
Aldefluor assay buffer containing an ALDH substrate, bodipy-
aminoacetaldehyde (BAAA) at 1.5 mM, and incubated for 40 min
at 37uC. To distinguish between ALDH-positive and -negative
cells, a fraction of cells was incubated under identical condition in
the presence of a 10-fold molar excess of the ALDH inhibitor,
diethylamino benzaldehyde (DEAB). This results in a significant
decrease in the fluorescent intensity of ALDH-positive cells and
was used to compensate the flow cytometer.
Lentivirus Infection of Cells
NMECs, SUM159, and MCF7 cell lines were infected with the
lentivirus expressing human PTEN shRNA or control lentiviruses.
The pLentilox 3.7 vector contains DsRed sequences in its
backbone for selection. Following 12–16 h of incubation in
suspension cultures of NMECs or monolayer cultures of breast
cancer cell lines, the viruses were replaced with fresh medium.
Implantation of Cells in NOD/SCID Mice
All mice were housed in the AAALAC-accredited specific
pathogen-free rodent facilities at the University of Michigan.
Mice were housed on sterilized, ventilated racks and supplied
with commercial chow and sterile water both previously
autoclaved. All experimentation involving live mice were
conducted in accordance with standard operating procedures
approved by the University Committee on the Use and Care of
Animals at the University of Michigan. The fat pads of three week
old NOD/SCID mice (NOD.CB17-Prkdcscid/J, stock number
001303) purchased from the Jackson Laboratories were cleared
and replaced with 1:1 mixture of irradiated and nonirradiated
human fibroblasts obtained from reduction mammoplasties.
Within 2–3 wk, human fibroblasts generated a humanized
mammary fat pad in mice. These resulting fat pads were injected
with NMECs infected with DsRed or PTEN shRNA lentiviral
vectors. A 60-d release 0.18-mg estrogen pellet (Innovative
Research of America) was implanted subcutaneously in each
mouse. The mice were killed after 4–8 wk and the fat pads were
analyzed for outgrowths.
An identical protocol was followed for injection of breast cancer
cell lines and xenografts, except that they were injected directly
into the fat pads of NOD/SCID mice. Indicated dilutions of cell
lines or xenografts were directly injected into fat pads of NOD/
SCID mice. We used five mice for each experiment.
Immunoblotting
Cells were lysed in Laemmli buffer, boiled, and subjected to
SDS-PAGE. The proteins were transferred onto Nitrocellulose
Membranes (Pierce) using semi dry Trans-Blot (Bio Rad
Laboratories). Blots were first incubated in TBS blocking buffer
containing either 2% milk or 2% BSA (for phospho-specific
antibodies) for 1 or 2 h at room temperature and then with the
respective primary antibodies diluted in TBST (containing 0.1%
Tween20 and 2% BSA) either overnight at 4uC, or 2 h at room
temperature. Subsequently, blots were washed and incubated with
appropriate secondary antibodies (GE Healthcare) in TBST and
detected using SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce).
Immunostaining
For immunohistochemistry, paraffin-embedded sections were
deparaffinized in xylene and rehydrated in graded alcohol.
Antigen enhancement was done by incubating the sections in
citrate buffer pH6 (Dakocytomation) as recommended. Staining
was done using peroxidase histostain-Plus Kit (Zymed) according
to the manufacturer’s protocol. Sections were incubated with
primary antibodies for 1 h. Following the incubation with broad-
spectrum secondary antibody and the HRP-conjugated streptavi-
din, AEC (Zymed) was used as substrate for peroxidase. Slides
were counter-stained with hematoxylin and coverslipped using
glycerin.
For fluorescent staining, cells were fixed with 95% methanol at
220uC for 10 min. After rehydrating in PBS, cells were incubated
with respective antibodies at room temperature for one hour,
washed and incubated 30 min with FITC-conjugated secondary
antibodies. The nuclei were stained with DAPI/antifade (Invitro-
gen) and coverslipped. Sections were examined with a fluorescent
microscope (Leica).
PTEN/Akt Regulates Mammary Stem/Progenitor Cells
PLoS Biology | www.plosbiology.org 12 June 2009 | Volume 7 | Issue 6 | e1000121
Statistical Analyses
Statistical differences for the number of mammospheres, GFP-
positive cells, Aldefluor assays and tumor growths were deter-
mined using Students t-test.
Supporting Information
Figure S1 b-catenin and phospho-GSK3-b analyzed in
Aldefluor-positive and Aldefluor-negative NMECs. Alde-
fluor-positive cells express b-catenin with nuclear localization as
compared to cytoplasmic b-catenin in Aldefluor-negative cells.
Aldefluor-positive cells also showed higher expression of phospho-
GSK3-b as compared to the Aldefluor-negative cells. Scale
bars = 100 mm.
Found at: doi:10.1371/journal.pbio.1000121.s001 (0.41 MB TIF)
Figure S2 PTEN knockdown increases normal mam-
mary stem/progenitor cells. (A) Mammary epithelial cells
from reduction mammoplasties contain 5–7% Aldefluor-positive
cells, and that increases to 15–18% in primary mammospheres.
PTEN knockdown increases the Aldefluor-positive population in
primary mammospheres as compared to that of control mammo-
spheres. (B) Down-regulation of PTEN using lentiviral shRNA also
maintains a higher level of Aldefluor-positive cells grown under
adherent conditions. (C) Phospho-Akt expression measured by
immunofluorescent staining in adherent versus mammosphere
cultures from control and PTEN knockdown cells is shown. A
higher Akt activity (p-Akt) was observed in cells with PTEN
knockdown cultured in both adherent culture and mammo-
spheres.
Found at: doi:10.1371/journal.pbio.1000121.s002 (0.53 MB TIF)
Figure S3 Infection of NMECs with a lentiviral b-catenin
shRNA produced a 50% reduction in the level of b-
catenin protein expression as well as a significant
reduction in active b-catenin as assessed by Western
blotting.
Found at: doi:10.1371/journal.pbio.1000121.s003 (0.06 MB TIF)
Figure S4 MCF7 cells were analyzed for the side
population as assessed by Hoechst dye exclusion, and
approximately one million SP or non-SP cells were
sorted. Subsequently, SP or non-SP cells were analyzed by the
Aldefluor assay. As indicated there was approximately a 2-fold
enrichment of Aldelfuor-positive population in SP as compared to
non-SP, which showed a similar percentage of Aldefluor-positive
cells as seen in unfractionated MCF7 cells.
Found at: doi:10.1371/journal.pbio.1000121.s004 (0.19 MB TIF)
Figure S5 PTEN knockdown activates Akt and accela-
rates tumor growth. A) Representative tumors from MCF7-
GFP control and MCF7-PTEN shRNA xenografts. (B) Tumor
sections from MCF7-GFP and MCF7-PTEN shRNA stained with
phospho-Akt antibodies demonstrated higher Akt phosphorylation
in PTEN knockdown MCF7 xenografts. (C) Relative tumor
growth of MCF7-GFP and MCF7-PTEN shRNA in NOD/SCID
mice.
Found at: doi:10.1371/journal.pbio.1000121.s005 (0.94 MB TIF)
Figure S6 Representative flow cytometry results of
Aldefluor assays performed on primary SUM159, MC1
or UM2 tumor xenografts. Treatment of cells with DEAB
resulted in inhibition of ALDH1 activity. Following the compen-
sation of the FITC channel based on DEAB inhibition, the cells
were gated and the Aldefluor-positive cells were analyzed in the
absence of the inhibitor. Perifosine or perifosine+docetaxel treated
tumors displayed a 75–90% reduction in the Aldefluor-positive
population as compared to the control or docetaxel treated
SUM159, MC1, or UM2 tumors.
Found at: doi:10.1371/journal.pbio.1000121.s006 (0.59 MB
TIF)
Figure S7 Reimplantation of primary SUM159 and MC1
tumors treated with saline, docetaxel, perifosine, or
both demonstrated different kinetics of tumor growth
in secondary mice. 50,000 or 10,000 cells from perifosine or
the combination of perifosine- and docetaxel-treated mice
produced a significant delay in growth in secondary mice.
Moreover, 1,000 tumor cells from control or docetaxel-treated
mice formed tumors when transplanted into secondary mice, while
the same number of cells from perifosine or the combination of
perifosine- and docetaxel-treated primary tumors failed to form
secondary tumors.
Found at: doi:10.1371/journal.pbio.1000121.s007 (0.17 MB
TIF)
Table S1 Mammary outgrowths in humanized NOD/
SCID mouse. Serial dilutions of NMECs infected with DsRed or
PTEN lentiviral shRNA were injected into the humanized
mammary fat pads of NOD/SCID mice. Implantation of as few
as 250 PTEN knockdown cells generated outgrowths in two out of
four mice (p,0.01). In contrast, 5,000 DsRed-infected NMECs
failed to generate outgrowths (p,0.005). In addition, PTEN
knockdown cells formed larger outgrowths as compared to control
DsRed cells.
Found at: doi:10.1371/journal.pbio.1000121.s008 (0.07 MB
TIF)
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